Naltrexone Ophthalmic - Ocunova Inc.
Alternative Names: OCU 001Latest Information Update: 28 Oct 2021
At a glance
- Originator Ocunova
- Class Analgesics; Anti-inflammatories; Antineoplastics; Antivirals; Cyclopropanes; Drug withdrawal therapies; Ethers; Eye disorder therapies; Irritable bowel syndrome therapies; Ketones; Morphinans; Non-opioid analgesics; Small molecules
- Mechanism of Action Opioid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Dry eyes
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for phase-I development in Dry-eyes in Unknown (Ophthalmic)
- 26 Mar 2018 Chemical structure information added
- 09 Feb 2018 Phase-I clinical trials in Dry eyes (Ophthalmic) (Before February 2018)